ONI’s $75 Million Series B Funding Round

In UK Wilson Sonsini Goodrich & Rosati, advised on the matter.

Wilson Sonsini Goodrich & Rosati advised ONI with a team including Michael Casey (Compliance & Regulatory), Daniel Glazer (Picture – Corporate M&A).

ONI, a biotechnology company democratizing the ability to observe single molecules in living cells with its desktop Nanoimager microscopy platform, announced the closing of a $75 million Series B funding round. The round was led by ARCH Venture Partners and Casdin Capital with participation from Section 32, ARTIS Ventures, Vertical Venture Partners, Axon Ventures, and private investors, including Paul Conley. Existing investors, including Oxford Science Enterprises, also participated in the round. 

Proceeds from the financing will be used to grow ONI’s commercial and R&D teams in the U.S. and Asia, driving technology adoption in those geographies. Funds will also be used to expand ONI’s portfolio of consumables and cloud-based software apps to become end-to-end automated solutions for application verticals.

The Wilson Sonsini team included: Daniel Glazer (Picture), Michael Labriola, Diviya Padman, Rui Ke, Abbie Currie, Michael Casey, Joshua Gruenspecht and John Lynch.
 

 

 

Involved fees earner: Michael Casey – Wilson Sonsini Goodrich & Rosati; Diviya Padman – Wilson Sonsini Goodrich & Rosati; Daniel Glazer – Wilson Sonsini Goodrich & Rosati; Joshua Gruenspecht – Wilson Sonsini Goodrich & Rosati; Rui Ke – Wilson Sonsini Goodrich & Rosati; Michael Labriola – Wilson Sonsini Goodrich & Rosati; John Lynch – Wilson Sonsini Goodrich & Rosati;

Law Firms: Wilson Sonsini Goodrich & Rosati;

Clients: ONI;

Author: Giulia Di Palma